CN105477421A - Pharmaceutical composition for preventing and treating thrombocytopenia after radiotherapy and application of pharmaceutical composition - Google Patents

Pharmaceutical composition for preventing and treating thrombocytopenia after radiotherapy and application of pharmaceutical composition Download PDF

Info

Publication number
CN105477421A
CN105477421A CN201510955561.1A CN201510955561A CN105477421A CN 105477421 A CN105477421 A CN 105477421A CN 201510955561 A CN201510955561 A CN 201510955561A CN 105477421 A CN105477421 A CN 105477421A
Authority
CN
China
Prior art keywords
parts
pharmaceutical composition
herba
radiotherapy
thrombocytopenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510955561.1A
Other languages
Chinese (zh)
Inventor
薛峰
徐海滨
邢杰
朱媚
王剑
吕明霞
郁万江
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Municipal Hospital
Original Assignee
Qingdao Municipal Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao Municipal Hospital filed Critical Qingdao Municipal Hospital
Priority to CN201510955561.1A priority Critical patent/CN105477421A/en
Publication of CN105477421A publication Critical patent/CN105477421A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/62—Nymphaeaceae (Water-lily family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention discloses a pharmaceutical composition for preventing and treating thrombocytopenia after radiotherapy and application of the pharmaceutical composition. The pharmaceutical composition is prepared from the following traditional Chinese medicinal raw materials in parts by weight: 11-17 parts of herba catharanthirosei, 19-25 parts of folium nelumbinis, 19-25 parts of falxleaf holly fern, 8-13 parts of rum ex japonicas, 12-18 parts of herba commelinae, 11-17 parts of cone of Chinese weeping cypress, 11-17 parts of rhizoma belamcandae, 6-12 parts of herba agrimoniae and 24-30 parts of lalang grass rhizome. The pharmaceutical composition disclosed by the invention has a certain effect on protecting platelet hemopoietic system injury caused by radiation; the pharmaceutical composition can be used for preventing or treating human body injury caused by radiotherapy on cancers or other diseases.

Description

Thrombocytopenic pharmaceutical composition and application thereof after a kind of control radiotherapy
Technical field
The present invention relates to thrombocytopenic pharmaceutical composition after a kind of control radiotherapy, belong to technical field of Chinese medicines.
Background technology
Along with the fast development of radiological medicine, the damage of ionizing radiation to human body more and more comes into one's own.Heavy dose of each system of Radiation On Human body all has damage, and wherein hemopoietic system and immune system are the most responsive.Ionizing radiation is nonspecific stimulation, acting on body causes organ, tissue, lymphocyte finally to cause function of immune system decline (RehaniMM.Challengesinradiationprotectionofpatientsforthe 21stcentury [J] .AJRAmJRoentgenol, 2013,200 (4): 762-764.).Due to hemopoietic system and immune system very responsive to ionizing radiation, strengthen in radiation protection and hemopoietic system and immune protection be very important.
Summary of the invention
The present inventor in conjunction with self clinical experience for many years, and by lot of experiments research and persistent exploration, finally obtains a kind of medicine for preventing and treating radiation-induced damage.
Particularly, the invention provides thrombocytopenic pharmaceutical composition and application thereof after a kind of control radiotherapy, its technical scheme overview is as follows:
Thrombocytopenic pharmaceutical composition after a kind of control radiotherapy, this pharmaceutical composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Herba Catharanthi Rosei 11-17 part, Folium Nelumbinis 19-25 part, Cyrtomium balansae (Christ) C. Chr. 19-25 part, Radix Rumicis Crispi 8-13 part, Herba Commelinae 12-18 part, Strobilus Cupressi 11-17 part, Rhizoma Belamcandae 11-17 part, Herba Agrimoniae 6-12 part, Rhizoma Imperatae 24-30 part.
Preferably, thrombocytopenic pharmaceutical composition after one control radiotherapy as above, is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Herba Catharanthi Rosei 14-16 part, Folium Nelumbinis 21-23 part, Cyrtomium balansae (Christ) C. Chr. 21-23 part, Radix Rumicis Crispi 9-11 part, Herba Commelinae 14-16 part, Strobilus Cupressi 14-16 part, Rhizoma Belamcandae 14-16 part, Herba Agrimoniae 8-10 part, Rhizoma Imperatae 26-28 part.
In the present invention's most preferred embodiment, after described control radiotherapy, thrombocytopenic pharmaceutical composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Herba Catharanthi Rosei 15 parts, 22 parts, Folium Nelumbinis, Cyrtomium balansae (Christ) C. Chr. 22 parts, Radix Rumicis Crispi 10 parts, Herba Commelinae 15 parts, Strobilus Cupressi 15 parts, Rhizoma Belamcandae 15 parts, Herba Agrimoniae 9 parts, Rhizoma Imperatae 27 parts.
The traditional Chinese medicinal material raw materials that pharmaceutical composition of the present invention is adopted in the preparation has following source: Herba Catharanthi Rosei selects the dry herb of Apocynaceae periwinkle plant Herba Catharanthi Rosei Catharanthusroseus (L.) GDon [VincaroseaL.].Folium Nelumbinis selects the dried leaves of nymphaeaceae plant lotus NelumbonuciferaGaertn..Cyrtomium balansae (Christ) C. Chr. selects the dry rhizome of Dryopteridaceae plant Cyrtomium balansae (Christ) C. Chr. Cyrtomiumbalansae (Christ) C.Chr..Radix Rumicis Crispi selects the dry root of Rumex gmelini Turcz Radix Rumicis Japonici R.japonicusHoutt..Herba Commelinae selects the dry aerial parts of Commelianaceae plant Herba Commelinae CommelinacommunisL..Strobilus Cupressi selects the dry fruit of Cupressaceae plant Cupressus funebris Endl. CupressusfunebrisEndl..Rhizoma Belamcandae selects the dry rhizome of irides Rhizoma Belamcandae Belamcandachinensis (L.) DC..Herba Agrimoniae selects the dry aerial parts of rosaceous plant Radix Agrimoniae AgrimoniapilosaLedeb.; Rhizoma Imperatae selects the dry rhizome of grass Herba Imperatae ImperatacylindricaBeauv.var.major (Nees) C.E.Hubb..
Thrombocytopenic pharmaceutical composition after any one control radiotherapy above-mentioned, it is oral liquid, granule, tablet, capsule; Preferably, thrombocytopenic pharmaceutical composition after any one control radiotherapy above-mentioned, it is granule.
Ionizing radiation can cause hemopoietic system, immune system and lymphsystem major injury, and after various dose roentgenization, a large amount of apoptosis appears in mouse peripheral blood cell.The present inventor is by studying tested material irradiated mice, and experimental result shows, and compares, disposable acceptance with normal group 60co gamma-rays irradiates the model group mice after 7d, and peripheral hemogram leukocyte and platelet count significantly decline, and can be used as radiation injury model.Compare with model group, the administration group mouse peripheral blood platelet count of various dose significantly raises, and shows that pharmaceutical composition of the present invention has good preventive and therapeutic effect to radiation-induced peripheral blood thrombocytopenia.Therefore, second object of the present invention is to provide a kind of pharmaceutical applications, i.e. the application of aforementioned pharmaceutical compositions after preparation control radiotherapy in thrombocytopenic medicine.
Compared with prior art, pharmaceutical composition of the present invention has certain protective action, the injury of human that the radiation treatment that can be used for prevention or Therapeutic cancer or other diseases brings to radiation-induced platelet hemopoietic system damage.
Detailed description of the invention
Be below concrete preparation example of the present invention and animal experiment example, technical scheme of the present invention and technique effect are done and describes further, but protection scope of the present invention be not limited to these embodiments.Every do not deviate from the present invention's design change or equivalent substituting include within protection scope of the present invention.
The preparation of embodiment 1 Chinese medicine extract
Take Herba Catharanthi Rosei 1.5kg, Folium Nelumbinis 2.2kg, Cyrtomium balansae (Christ) C. Chr. 2.2kg, Radix Rumicis Crispi 1.0kg, Herba Commelinae 1.5kg, Strobilus Cupressi 1.5kg, Rhizoma Belamcandae 1.5kg, Herba Agrimoniae 0.9kg and Rhizoma Imperatae 2.7kg, merge, pulverize, decoct with water twice, first time adds water as 12 times amount of medical material gross weight, decoct 2h, second time adds water as 10 times amount of medical material gross weight, decoct 1.5h, collecting decoction, 0.07MPa, the extractum that relative density is 1.15 is evaporated under 65 DEG C of conditions, adding ethanol makes alcohol content reach 75% (v/v), stir, leave standstill 24 hours, filter, filtrate is at 0.07MPa, concentrating under reduced pressure under 65 DEG C of conditions, reclaim ethanol simultaneously, then (condition is inlet temperature is 100 DEG C to spraying dry, leaving air temp is 80 DEG C, temperature of charge is 80 DEG C, atomizing pressure is 0.2 MPa, spray velocity is 5ml/s), pulverized 80 mesh sieves, obtain Chinese medicine extract clear paste powder.
Embodiment 2 Chinese medicine extract causes thrombocytopenic impact test to mice radiation
Female KM kind mice, weight 20 ~ 24g, is divided into the high, medium and low dosage group of Normal group, model control group and Chinese medicine, totally 5 groups at random, often organizes 10.After on-test, Chinese medicine high, medium and low dosage group mice gives Chinese medicine extract clear paste powder (preparing by the formulation and technology of embodiment 1), dosage is respectively 0.72,0.36,0.18g/kg, administration volume 10mL/kg, Normal group and model control group give isometric(al) distilled water.Every day gavage 1 time, continuous 14d.Below respectively organize gavage the 7th day, except Normal group, all the other are group all execution 1 property respectively 60the total irradiation of Co gamma-rays, absorption accumulated dose is 4Gy, and close rate is 1Gy/min, irradiation time 4min.Irradiate administration in the 7th day after modeling to terminate, get every mice and carry out eyeball and get blood, add in EDETATE SODIUM salt anticoagulant tube, detect peripheral blood leucocyte and platelet levels.
Can be found out by the test data statistical result of table 1, model control group leukocyte and platelet are significantly lower than Normal group (P<0.01), each administration group leucocyte level compares model control group there was no significant difference, and platelet levels is compared model control group and is significantly raised, and has pole significance statistical significance (P<0.01).This imply that pharmaceutical composition of the present invention has protection preferably to thrombocytopenia caused by radiation and promotes restitution.
Table 1 respectively group peripheral blood leucocyte and platelet levels compares (× 10 9/ L)
Compare with model control group, * P<0.05; Compare with model control group, * * P<0.01.

Claims (6)

1. thrombocytopenic pharmaceutical composition after a control radiotherapy, it is characterized in that, this pharmaceutical composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Herba Catharanthi Rosei 11-17 part, Folium Nelumbinis 19-25 part, Cyrtomium balansae (Christ) C. Chr. 19-25 part, Radix Rumicis Crispi 8-13 part, Herba Commelinae 12-18 part, Strobilus Cupressi 11-17 part, Rhizoma Belamcandae 11-17 part, Herba Agrimoniae 6-12 part, Rhizoma Imperatae 24-30 part.
2. prevent and treat thrombocytopenic pharmaceutical composition after radiotherapy according to claim 1, it is characterized in that, this pharmaceutical composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Herba Catharanthi Rosei 14-16 part, Folium Nelumbinis 21-23 part, Cyrtomium balansae (Christ) C. Chr. 21-23 part, Radix Rumicis Crispi 9-11 part, Herba Commelinae 14-16 part, Strobilus Cupressi 14-16 part, Rhizoma Belamcandae 14-16 part, Herba Agrimoniae 8-10 part, Rhizoma Imperatae 26-28 part.
3. prevent and treat thrombocytopenic pharmaceutical composition after radiotherapy according to claim 2, it is characterized in that, this pharmaceutical composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Herba Catharanthi Rosei 15 parts, 22 parts, Folium Nelumbinis, Cyrtomium balansae (Christ) C. Chr. 22 parts, Radix Rumicis Crispi 10 parts, Herba Commelinae 15 parts, Strobilus Cupressi 15 parts, Rhizoma Belamcandae 15 parts, Herba Agrimoniae 9 parts, Rhizoma Imperatae 27 parts.
4. thrombocytopenic pharmaceutical composition after preventing and treating radiotherapy according to claim 1 or 2 or 3, is characterized in that, this pharmaceutical composition is oral formulations.
5. prevent and treat thrombocytopenic pharmaceutical composition after radiotherapy according to claim 4, it is characterized in that: described oral formulations is oral liquid, granule, tablet, capsule.
6. the application of the traditional Chinese medicinal material raw materials compositions according to claim 1 or 2 or 3 after preparation control radiotherapy in thrombocytopenic medicine.
CN201510955561.1A 2015-12-17 2015-12-17 Pharmaceutical composition for preventing and treating thrombocytopenia after radiotherapy and application of pharmaceutical composition Pending CN105477421A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510955561.1A CN105477421A (en) 2015-12-17 2015-12-17 Pharmaceutical composition for preventing and treating thrombocytopenia after radiotherapy and application of pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510955561.1A CN105477421A (en) 2015-12-17 2015-12-17 Pharmaceutical composition for preventing and treating thrombocytopenia after radiotherapy and application of pharmaceutical composition

Publications (1)

Publication Number Publication Date
CN105477421A true CN105477421A (en) 2016-04-13

Family

ID=55664931

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510955561.1A Pending CN105477421A (en) 2015-12-17 2015-12-17 Pharmaceutical composition for preventing and treating thrombocytopenia after radiotherapy and application of pharmaceutical composition

Country Status (1)

Country Link
CN (1) CN105477421A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1785270A (en) * 2004-12-06 2006-06-14 上海美迪西生物医药有限公司 Chinese medicine used for increasing leucocyle, treating thrombocytopenia anl its preparation method
CN101513504A (en) * 2009-03-24 2009-08-26 李�杰 Chinese herbal medicine for remedying thrombocytopenia after radiochemotherapy
CN102512598A (en) * 2012-01-06 2012-06-27 马永波 Medicinal composition for arresting bleeding and generating blood platelets

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1785270A (en) * 2004-12-06 2006-06-14 上海美迪西生物医药有限公司 Chinese medicine used for increasing leucocyle, treating thrombocytopenia anl its preparation method
CN101513504A (en) * 2009-03-24 2009-08-26 李�杰 Chinese herbal medicine for remedying thrombocytopenia after radiochemotherapy
CN102512598A (en) * 2012-01-06 2012-06-27 马永波 Medicinal composition for arresting bleeding and generating blood platelets

Similar Documents

Publication Publication Date Title
CN102935133B (en) Traditional Chinese medicine composition for treating rheumatic arthritis as well as preparation method and application thereof
CN1330359C (en) Chinese medicine preparation for treating AIDS and process thereof
CN105477421A (en) Pharmaceutical composition for preventing and treating thrombocytopenia after radiotherapy and application of pharmaceutical composition
CN101347522A (en) Nano &#39;Shuang Hualian&#39; injection preparation for fowl and preparation thereof
CN102908443A (en) Medicinal composition for therapy or adjuvant therapy of aids, preparation method of medicinal composition and application of medicinal composition
CN105944031A (en) Anti-radiation traditional Chinese medicine and preparation method
CN104888149A (en) Drug for treating cervical cancer and preparation method for drug
CN105641377A (en) Traditional Chinese medicinal decoction for treating swine bronchial pneumonia and preparation method of traditional Chinese medicinal decoction
CN104042677A (en) Use of Manglietia fruit extractive in preparation of orthopaedic anti-inflammatory and analgesic medicine
CN103599265A (en) Compound traditional Chinese medicine for radiation protection
CN103877297A (en) Medicinal composition for treating infantile hernia and preparation method of medicinal composition
CN102641480A (en) Traditional Chinese medicine composite used for treating microcirculation disturbance and preparation method thereof
CN103316110A (en) Use of medicine in simple schizophrenia treatment medicines
CN103830371B (en) Medicinal preparation for promoting cerebral micro-circulation
CN101361811A (en) Radiation resistant traditional Chinese medicine combination and preparation method thereof
CN105395908A (en) Application of medicine composition in preparing medicine for treating rheumatic arthritis
CN103989894A (en) Lozenge capable of improving anoxia endurance, and preparation method and application thereof
CN107233540A (en) A kind of Chinese medicine composition for treating rheumatoid arthritis
CN105288285A (en) Medicinal preparation for treating chronic bronchitis
CN105396105A (en) A method of preparing a traditional Chinese medicine composition for preventing and treating recurrent common cold in children
CN104888123A (en) Preparation for infantile respiratory tract infection as well as preparation method and detection method thereof
CN104208588A (en) Traditional Chinese medicine preparation for treating tumor diseases and preparation method
CN104189846A (en) Traditional Chinese medicine composition used as radiotherapy and chemotherapy sensitizing agent and preparation method thereof
CN103316126A (en) Traditional Chinese medicine for treating schizophrenia
CN114984171A (en) Traditional Chinese medicine composition for treating systemic lupus erythematosus as well as preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160413

RJ01 Rejection of invention patent application after publication